Q1 10-Q through 3/31/26. BCA with Carvix signed 3/30/26 (domestication then merger); closing needs S-4 effectiveness, shareholder votes, Nasdaq listing, NTA/penny-stock test, and Minimum Cash after redemptions/expenses—Outside Date 9/30/26. Combination Period auto-extended to 2/10/27 on DA. Trust $174,928,579 on 17.25M redeemable Class A at $10.00 redemption value; no cash outside trust, sponsor-funded WC, going-concern language. BC not closed as of 3/31/26. Public rights: one right = 0.20 (1/5) Class A share at combination.

Conversion 1/5